BSE - SMEUpcoming
Goldline Pharmaceutical Limited
Company websiteGoldline Pharmaceutical Limited plans to raise ₹27,00,000 crore via IPO. That includes a fresh infusion of ₹27,00,000 crore and an OFS worth ₹0 crore.
Apply from 12-05-2026 until 14-05-2026. Allotment and tentative listing are scheduled for 15-05-2026 and 19-05-2026. Quick tip: check lot size and valuation before bidding.
Start Date12-05-2026
End Date14-05-2026
Listing Date19-05-2026
Allotment Date15-05-2026
Current Price₹0
GMP₹6 (13.95%)
Lot Size3000 Shares
Subscription0 Times
Face Value₹10 per share
Listing atBSE
Issue Price₹41 - ₹43
Pre Issue₹69,00,000
Post Issue₹96,00,000
Issue Size₹27,00,000
(aggregating up to 11.61 Cr)
(aggregating up to 11.61 Cr)
Fresh Issue₹27,00,000
(aggregating up to 11.61 Cr)
(aggregating up to 11.61 Cr)
Offer For Sale-
The Grey Market Premium (GMP) for Goldline Pharmaceutical Limited is currently around ₹6 (13.95%). This indicates an estimated listing price of approximately ₹47 based on the latest market sentiment. Please note that GMP values are unofficial and can change frequently as they depend on demand, market conditions, and investor activity.
Gmp Details
| Last Updated | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
07 May 2026, 04:33 | ₹43 | ₹6 | ₹49 (13.95%) |
Financials overview In Crores
Here is a quick look at the recent financial performance of Goldline Pharmaceutical Limited . The numbers below ( In Crores ) show how the company’s revenue and profits have changed over the last few years. This helps investors understand how strongly the business is growing and how stable its financial health is before applying for the IPO.
Key Performance
| KPI | Dec-25 | Mar-25 | Mar-24 |
|---|---|---|---|
EPS | 3.22 | 4.10 | 3.01 |
ROE | 21.02 | 35.83 | 31.31 |
ROCE | 0 | 0 | 0 |
RONW | 0 | 0 | 0 |
PRE IPO(PE) | 0 | 10.47 | 0 |
POST IPO(PE) | 14.56 | 0 | 0 |
The IPO reservation for Goldline Pharmaceutical Limited shows how the total issue is divided among different investor categories. This includes allocations for Retail Investors, Qualified Institutional Buyers (QIBs), and Non-Institutional Investors (NIIs). Understanding the reservation structure helps investors know how much of the issue is set aside for their category before applying.
IPO Reservation
| Category | Shares Offers | No. of Shares |
|---|---|---|
Anchor | 27.11% | 7,32,000 |
QIB | 20.00% | 5,40,000 |
HNI | 14.44% | 3,90,000 |
RETAIL | 33.33% | 9,00,000 |
Market Maker | 5.11% | 1,38,000 |
TOTAL | 100.00% | 27,00,000 |
Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
Retail (Min) | 2 | 6,000 | ₹2,58,000 | |
sHNI | 3 | 9,000 | ₹3,87,000 | |
bHNI | 8 | 24,000 | ₹10,32,000 |
Below you can find the official contact details of Goldline Pharmaceutical Limited along with the registrar handling the IPO process. This information helps investors reach out for queries related to the company or for checking the allotment status and application updates once the IPO process begins.
Company Details
Email: info@goldlinepharma.in
Phone: +91 712 2786666
Website: https://www.goldlinepharma.in/
Address: 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015